On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Immunic (IMUX) stock fell after the company said it plans to continue its Phase 3 ENSURE program for lead drug IMU-838 in ...

Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...

Immunic (IMUX) is a clinical-stage biotechnology company focused on developing small-molecule therapies for treating chronic inflammatory and autoimmune diseases. In our last few articles ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Tuesday announced positive outcome from the interim futility analysis of its Phase 3 ENSURE program evaluating ...

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline ...

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Option chain shows key data for Immunic's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Immunic.

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...